NCT06237712Active, not recruiting
Explorative Study to Investigate the Acid-base Response to Sodium and Potassium Salts in Patients With Chronic Kidney Disease.
Source: ClinicalTrials.gov · Last updated 12 Aug 2025
Brief summary (registry, in English)
With this research the investigators want to study how patients with chronic kidney disease respond to different sodium- and potassium salts. Potassium salts can prevent kidney damage and cardiovascular disease, however patients with chronic kidney disease can responds differently. Extra potassium can increase the amount of potassium in the blood and extra chloride can cause acidosis. With this study the investigators will gain more insight in how patients with chronic kidney disease respond to sodium and potassium salts and which one is more favorable.This information can then be used to guide the application of salt substitutes and dietary adjustments in patients with chronic kidney disease.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- First submitted
- 25 Jul 2023
- Start date
- 26 Jan 2024
- Primary completion date
- 21 Mar 2025
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Chronic kidney disease
- NCT number
- NCT06237712
What you commit to
- Study type: Interventional
- Planned participants: 31
- From 26 Jan 2024 to the primary completion date, 21 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients using double RAAS blockade (i.e., ACE-inhibitor + ARB).
- Kidney transplant recipients
- Patients with previous history of ventricular cardiac arrhythmia
- Patients with chronic respiratory acidosis in previous medical history
Other illness
- Patients with an active gastro-intestinal ulcer
Lab values
- Use of any of the following drugs or supplements: mineralocorticoid receptor antagonists, potassium-sparing diuretics, oral potassium binders, immunosuppressive medication, tolvaptan, acetazolamide, topiramate, sodium bicarbonate.
- Metabolic alkalosis (plasma bicarbonate \>27 mmol/L) at last outpatient visit
- Hyperkalemia (plasma potassium \>5.5 mmol/L) at V0
Other
- Patients with a life expectancy \< 6 months
- Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team
- Women who are pregnant, breastfeeding or consider pregnancy in the coming 7 weeks
Who the study is looking for
- Adult patients (≥ 18 years)
- CKD G3b or G4 (44 - 15 ml/min/1.73 m2)
- Use of RAAS-I (ACE-inhibitor or angiotensin receptor blocker, ARB)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ErasmusMC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.